16th Jul 2018 17:31
PRESS RELEASE
16 July 2018
Notification re Change of Auditors
Ergomed plc ("Ergomed" or the "Company")
At the Company's Annual General Meeting held on 12 June 2018, a resolution to appoint KPMG as Ergomed's auditors was proposed and approved by shareholders.
Ergomed now announces that on 13 July 2018 it wrote to shareholders explaining that, as planned, Deloitte LLP had resigned as auditor and KPMG had been appointed as the Company's new auditor. And as required by the Companies Act the Company also sent to shareholders a statement of Deloitte's reasons for their ceasing to hold office (namely that the directors of Ergomed have decided to appoint another firm as auditors).
This announcement is being made pursuant to the requirements of AIM Rule 20.
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 503 205 | ||
Stuart Jackson (Chief Financial Officer) | |||
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 | ||
Michael Meade / Freddie Barnfield (Nominated Adviser) | |||
James Black (Joint Broker) | |||
N+1 Singer | Tel: +44 (0) 20 7496 3000 | ||
Aubrey Powell (Joint Broker) | |||
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 | ||
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Olivia Manser | |||
MC Services - for Continental European enquiries | Tel: +49 211 5292 5222 | ||
Anne Hennecke | |||
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com.
Related Shares:
ERGO.L